Baidu
map

五大方面更新!中国疾控中心发布《中国流感疫苗预防接种技术指南(2022-2023)》

2022-08-26 中国疾控动态 中国疾控动态

该指南内容主要包括流感病原学、流行病学、季节性等特征,不同人群流感所致的健康和经济负担,流感疫苗种类及免疫原性、效力、效果、成本收益、安全性,及2022-2023年度接种建议。

点击此处查看指南原文

 

目前,全球新冠肺炎疫情严重流行态势仍在持续,今年夏季我国南方部分省份出现夏季流感流行高峰,今冬明春可能会出现新冠与流感等呼吸道传染病叠加流行的风险。流感是疫苗可预防性疾病,为尽可能降低流感对新冠疫情防控的干扰,更好地指导我国流感预防控制和疫苗应用工作,中国疾控中心组织有关专家及时编制和印发了《中国流感疫苗预防接种技术指南(2022-2023)》。该指南内容主要包括流感病原学、流行病学、季节性等特征,不同人群流感所致的健康和经济负担,流感疫苗种类及免疫原性、效力、效果、成本收益、安全性,及2022-2023年度接种建议。

结合今年新冠肺炎疫情形势,优先推荐以下重点和高风险人群及时接种:医务人员,包括临床救治人员、公共卫生人员、卫生检疫人员等;大型活动参加人员和保障人员;养老机构、长期护理机构、福利院等人群聚集场所脆弱人群及员工;重点场所人群,如托幼机构、中小学校的教师和学生,监所机构的在押人员及工作人员等;其他流感高风险人群,包括60岁及以上的居家老年人、6月龄~5岁儿童、慢性病者、6月龄以下婴儿的家庭成员和看护人员以及孕妇。

结合WHO立场文件及其关于新冠疫苗和流感疫苗同时接种的建议,以及目前国际上发表的和我国已开展的有限的关于同时接种研究的初步结果,经审慎考虑,认为18岁及以上人群可在一次接受免疫服务时,在两侧肢体分别接种灭活流感疫苗和新冠疫苗;18岁以下的人群,建议流感疫苗与新冠疫苗接种间隔仍大于14天。

关于接种剂次,对于灭活流感疫苗,6月龄~8岁儿童首次接种流感疫苗的应接种2剂次,间隔≥4周;2021-2022年度或以前接种过1剂次或以上流感疫苗的儿童,建议接种1剂次;9岁及以上儿童和成人仅需接种1剂次。对于减毒活流感疫苗,无论是否接种过流感疫苗,仅接种1剂次。

本指南是中国疾控中心国家免疫规划技术工作组流感疫苗工作组综合国内外最新研究进展,在《中国流感疫苗预防接种技术指南(2021-2022)》(简称“2021年版指南”)的基础上进行更新和修订形成,指南更新的内容主要包括以下几个方面:第一,增加了新的研究证据,尤其是我国的研究结果,包括流感疾病负担、疫苗效果、疫苗安全性监测、疫苗预防接种成本效果等;第二,更新了一年来国家出台的有关流感防控政策和措施;第三,更新了我国2022-2023年度国内批准上市及批签发的流感疫苗种类;第四,更新了本年度三价和四价流感疫苗组份;第五,更新了2022-2023年度的流感疫苗接种建议。

本指南适用于疾控机构、医疗机构、妇幼保健机构和接种单位等从事流感防治相关的专业人员。

下载:中国流感疫苗预防接种技术指南(2022-2023)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2048316, encodeId=2152204831665, content=<a href='/topic/show?id=f8062191152' target=_blank style='color:#2F92EE;'>#中国疾控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21911, encryptionId=f8062191152, topicName=中国疾控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Wed Nov 09 18:30:07 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953646, encodeId=8425195364677, content=<a href='/topic/show?id=ebace05389b' target=_blank style='color:#2F92EE;'>#疫苗预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70538, encryptionId=ebace05389b, topicName=疫苗预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Mon Apr 03 10:30:07 CST 2023, time=2023-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1980820, encodeId=d6b1198082022, content=<a href='/topic/show?id=03e06533e26' target=_blank style='color:#2F92EE;'>#流感疫苗预防接种技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65337, encryptionId=03e06533e26, topicName=流感疫苗预防接种技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Thu Feb 23 21:30:07 CST 2023, time=2023-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405380, encodeId=63fa1405380b0, content=<a href='/topic/show?id=3f67e0632c0' target=_blank style='color:#2F92EE;'>#疾控中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70632, encryptionId=3f67e0632c0, topicName=疾控中心)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/0AD7956C8522FF8EF9A242DC5569528A/100, createdBy=d51a2536255, createdName=zutt, createdTime=Sat Aug 27 06:30:07 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530264, encodeId=844f15302641e, content=<a href='/topic/show?id=5b3d21912a7' target=_blank style='color:#2F92EE;'>#中国疾控中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21912, encryptionId=5b3d21912a7, topicName=中国疾控中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbd912073499, createdName=tcm103hq, createdTime=Sat Aug 27 06:30:07 CST 2022, time=2022-08-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2048316, encodeId=2152204831665, content=<a href='/topic/show?id=f8062191152' target=_blank style='color:#2F92EE;'>#中国疾控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21911, encryptionId=f8062191152, topicName=中国疾控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Wed Nov 09 18:30:07 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953646, encodeId=8425195364677, content=<a href='/topic/show?id=ebace05389b' target=_blank style='color:#2F92EE;'>#疫苗预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70538, encryptionId=ebace05389b, topicName=疫苗预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Mon Apr 03 10:30:07 CST 2023, time=2023-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1980820, encodeId=d6b1198082022, content=<a href='/topic/show?id=03e06533e26' target=_blank style='color:#2F92EE;'>#流感疫苗预防接种技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65337, encryptionId=03e06533e26, topicName=流感疫苗预防接种技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Thu Feb 23 21:30:07 CST 2023, time=2023-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405380, encodeId=63fa1405380b0, content=<a href='/topic/show?id=3f67e0632c0' target=_blank style='color:#2F92EE;'>#疾控中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70632, encryptionId=3f67e0632c0, topicName=疾控中心)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/0AD7956C8522FF8EF9A242DC5569528A/100, createdBy=d51a2536255, createdName=zutt, createdTime=Sat Aug 27 06:30:07 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530264, encodeId=844f15302641e, content=<a href='/topic/show?id=5b3d21912a7' target=_blank style='color:#2F92EE;'>#中国疾控中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21912, encryptionId=5b3d21912a7, topicName=中国疾控中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbd912073499, createdName=tcm103hq, createdTime=Sat Aug 27 06:30:07 CST 2022, time=2022-08-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2048316, encodeId=2152204831665, content=<a href='/topic/show?id=f8062191152' target=_blank style='color:#2F92EE;'>#中国疾控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21911, encryptionId=f8062191152, topicName=中国疾控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Wed Nov 09 18:30:07 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953646, encodeId=8425195364677, content=<a href='/topic/show?id=ebace05389b' target=_blank style='color:#2F92EE;'>#疫苗预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70538, encryptionId=ebace05389b, topicName=疫苗预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Mon Apr 03 10:30:07 CST 2023, time=2023-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1980820, encodeId=d6b1198082022, content=<a href='/topic/show?id=03e06533e26' target=_blank style='color:#2F92EE;'>#流感疫苗预防接种技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65337, encryptionId=03e06533e26, topicName=流感疫苗预防接种技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Thu Feb 23 21:30:07 CST 2023, time=2023-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405380, encodeId=63fa1405380b0, content=<a href='/topic/show?id=3f67e0632c0' target=_blank style='color:#2F92EE;'>#疾控中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70632, encryptionId=3f67e0632c0, topicName=疾控中心)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/0AD7956C8522FF8EF9A242DC5569528A/100, createdBy=d51a2536255, createdName=zutt, createdTime=Sat Aug 27 06:30:07 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530264, encodeId=844f15302641e, content=<a href='/topic/show?id=5b3d21912a7' target=_blank style='color:#2F92EE;'>#中国疾控中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21912, encryptionId=5b3d21912a7, topicName=中国疾控中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbd912073499, createdName=tcm103hq, createdTime=Sat Aug 27 06:30:07 CST 2022, time=2022-08-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2048316, encodeId=2152204831665, content=<a href='/topic/show?id=f8062191152' target=_blank style='color:#2F92EE;'>#中国疾控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21911, encryptionId=f8062191152, topicName=中国疾控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Wed Nov 09 18:30:07 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953646, encodeId=8425195364677, content=<a href='/topic/show?id=ebace05389b' target=_blank style='color:#2F92EE;'>#疫苗预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70538, encryptionId=ebace05389b, topicName=疫苗预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Mon Apr 03 10:30:07 CST 2023, time=2023-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1980820, encodeId=d6b1198082022, content=<a href='/topic/show?id=03e06533e26' target=_blank style='color:#2F92EE;'>#流感疫苗预防接种技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65337, encryptionId=03e06533e26, topicName=流感疫苗预防接种技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Thu Feb 23 21:30:07 CST 2023, time=2023-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405380, encodeId=63fa1405380b0, content=<a href='/topic/show?id=3f67e0632c0' target=_blank style='color:#2F92EE;'>#疾控中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70632, encryptionId=3f67e0632c0, topicName=疾控中心)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/0AD7956C8522FF8EF9A242DC5569528A/100, createdBy=d51a2536255, createdName=zutt, createdTime=Sat Aug 27 06:30:07 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530264, encodeId=844f15302641e, content=<a href='/topic/show?id=5b3d21912a7' target=_blank style='color:#2F92EE;'>#中国疾控中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21912, encryptionId=5b3d21912a7, topicName=中国疾控中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbd912073499, createdName=tcm103hq, createdTime=Sat Aug 27 06:30:07 CST 2022, time=2022-08-27, status=1, ipAttribution=)]
    2022-08-27 zutt
  5. [GetPortalCommentsPageByObjectIdResponse(id=2048316, encodeId=2152204831665, content=<a href='/topic/show?id=f8062191152' target=_blank style='color:#2F92EE;'>#中国疾控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21911, encryptionId=f8062191152, topicName=中国疾控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Wed Nov 09 18:30:07 CST 2022, time=2022-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953646, encodeId=8425195364677, content=<a href='/topic/show?id=ebace05389b' target=_blank style='color:#2F92EE;'>#疫苗预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70538, encryptionId=ebace05389b, topicName=疫苗预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Mon Apr 03 10:30:07 CST 2023, time=2023-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1980820, encodeId=d6b1198082022, content=<a href='/topic/show?id=03e06533e26' target=_blank style='color:#2F92EE;'>#流感疫苗预防接种技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65337, encryptionId=03e06533e26, topicName=流感疫苗预防接种技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Thu Feb 23 21:30:07 CST 2023, time=2023-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405380, encodeId=63fa1405380b0, content=<a href='/topic/show?id=3f67e0632c0' target=_blank style='color:#2F92EE;'>#疾控中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70632, encryptionId=3f67e0632c0, topicName=疾控中心)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/0AD7956C8522FF8EF9A242DC5569528A/100, createdBy=d51a2536255, createdName=zutt, createdTime=Sat Aug 27 06:30:07 CST 2022, time=2022-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530264, encodeId=844f15302641e, content=<a href='/topic/show?id=5b3d21912a7' target=_blank style='color:#2F92EE;'>#中国疾控中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21912, encryptionId=5b3d21912a7, topicName=中国疾控中心)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbd912073499, createdName=tcm103hq, createdTime=Sat Aug 27 06:30:07 CST 2022, time=2022-08-27, status=1, ipAttribution=)]

相关资讯

接种流感疫苗,能够大幅降低阿尔茨海默病风险?

接种至少一剂流感疫苗的人在四年内患阿尔茨海默病 (AD) 的风险降低了40% 。

Science Translational Medicine:通用型流感疫苗来了,已开展人体临床试验

研究开发了一种通用型流感疫苗,由灭活的全病毒禽流感亚型 A 型流感疫苗组成,这种流感病毒构成了当前大多数流感病例。该疫苗由 H1N9、H3N8、H5N1 和 H7N3 亚型组成,还包括多种病毒蛋白。

接种流感疫苗,能够大幅降低阿尔茨海默病风险?

老年人接种流感疫苗可以在未来几年降低阿尔茨海默病患病风险,而且这种防护作用随着接种次数而增强,那些每年持续接种流感疫苗的老年人患阿尔茨海默病的风险最低。

世界卫生组织关于流感疫苗立场文件

十年期间,流感以及流感疫苗研究领域产生了许多新的成果,新的流行病学证据和新的流感疫苗应用以及效果评价。最新立场文件更新的主要内容,包括流感流行病学、风险人群、免疫接种对疾病的影响、流感疫苗及其效果与安

流感疫苗,可保护心血管病高危或患病人群!Meta分析

根据2019年发表的数据,中国流感疫苗总覆盖率不足2%。

Nature:流感疫苗能降低新冠重症90%,有奇效!这,啥意思?

《自然》近日发表文章称,一项对卡塔尔3万多名卫生保健工作者的研究发现,流感疫苗可能可以预防新冠病毒,尤其是在新冠重症防护方面效果显著。不过,目前尚不清楚这其中的原因,也不确定流感疫苗对新冠病毒的防护效

Baidu
map
Baidu
map
Baidu
map